Navigation Links
Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
Date:11/15/2009

SOUTH SAN FRANCISCO, Calif., Nov. 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will hold a teleconference and webcast at 8:00 a.m. Eastern Time tomorrow, Monday, November 16, to discuss results from its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in patients with small cell lung cancer.

Conference Call and Webcast Information

To participate in the live call on Monday, November 16, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), please dial 866-816-1982 from the U.S. or 913-312-0857 for international callers. The Webcast can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also has conducted a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

<
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
2. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
3. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
4. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
5. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
6. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
7. Poniard Pharmaceuticals Receives Going Concern Qualification
8. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
9. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
10. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... (PRWEB) September 21, 2014 "I wanted ... without having to consume sugary, foul-tasting energy drinks," said ... not always just want to drink plain, old coffee. ... energy booster." , He developed ENERG CHEWING GUM to ... with weight loss. The formula contains nutritious vitamins, minerals ...
(Date:9/21/2014)... The Illinois Joining Forces Behavioral ... statewide symposium ( tinyurl.com/ILBHC14 ) focused on improving ... Sponsored by the VNA Foundation, Thresholds, Illinois Department ... Health & Disability Advocates, the symposium will be ... in Springfield, IL. The symposium features keynote ...
(Date:9/21/2014)... 21, 2014 The Electronic Medical ... supports electronic medical records (EMR) and electronic health ... healthcare legislation during the past five years and ... the five years to 2019. The 2009 Health ... established Medicare and Medicaid incentives to encourage the ...
(Date:9/21/2014)... Discount-Dress.com, a company that specializes in fashion garments ... implement a new shopping cart software on its website. ... Furthermore, the company has unveiled a new collection of ... items come in fashionable designs; all of them are ... off. "We are happy to release the new beach ...
(Date:9/21/2014)... accommodate the ever-growing customer base, Angeldress.co.uk decided to implement ... the company has unveiled its 2014 vintage wedding ... gowns, Angeldress.co.uk wants to make sure that all customers ... Its high quality vintage wedding outfits are now available ... off. , Online shopping is becoming more and more ...
Breaking Medicine News(10 mins):Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2
... , ... procedure to reshape the inner vaginal lips, may be considered medically necessary when large or ... cases like these, Chicago-area plastic surgeon Allan Parungao, MD, works with patients to help get ... ...
... Readers can ... Maroema Cook Book” by Mamta Reid of Tokyo’s MAROEMA Vegetarian Catering. , ... (PRWEB) May 6, 2010 -- Individuals looking for ... of “A must have...The Maroema Cook Book” by Mamta Reid. With a lightweight, compact design ...
... with dementia are six times more likely to develop the ... to results of a 12-year study led by Johns Hopkins, ... the researchers saw among caregivers was on par with the ... Alzheimer,s disease, they report in the May Journal of ...
... 6, 2010 Results from the SPIRIT IV clinical ... Therapeutics (TCT) 2009 scientific symposium, were published today in ... Data from the trial, a large-scale multi-center study of ... stents demonstrated enhanced safety and efficacy in the treatment ...
... outbreak began, finds this flu had new targets , WEDNESDAY, ... flu first appeared, the World Health Organization has issued perhaps ... , "Here,s the definitive reference that shows in black-and-white what ... Dr. John Treanor, a professor of medicine and of microbiology ...
... ... the Global Embolization Symposium and Technologies (GEST) Meeting. Focus is on Benefit of Embolization ... ... a U.S.-based subsidiary of Terumo Corporation, today announced its educational program for the 4th ...
Cached Medicine News:Health News:Labiaplasty May Be Covered by Insurance, Notes Chicago-area Plastic Surgeon Allan Parungao, MD 2Health News:Labiaplasty May Be Covered by Insurance, Notes Chicago-area Plastic Surgeon Allan Parungao, MD 3Health News:Labiaplasty May Be Covered by Insurance, Notes Chicago-area Plastic Surgeon Allan Parungao, MD 4Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly &#8220;A must have...The Maroema Cook Book&#8221; 2Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly &#8220;A must have...The Maroema Cook Book&#8221; 3Health News:Spouses who care for partners with dementia at sixfold higher risk of same fate 2Health News:Spouses who care for partners with dementia at sixfold higher risk of same fate 3Health News:Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent 2Health News:H1N1 Often Hit the Young and Healthy 2Health News:H1N1 Often Hit the Young and Healthy 3Health News:Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting 2Health News:Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting 3Health News:Terumo Medical Corporation Announces its Program for the Global Embolization Symposium and Technologies (GEST) Meeting 4
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... 19, 2014 Intarcia Therapeutics, Inc. ... for its lead candidate ITCA 650 (continuous subcutaneous delivery ... baseline HbA1c levels at the 50 th Annual ... Diabetes (EASD). Data from the open-label, phase 3 FREEDOM-HBL ... sugar in patients with poorly controlled type 2 diabetes. ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... , SAN DIEGO, Sept. 8 ... ("Stemedica"), a world leader in stem cell research and manufacturing, ... and Trademark Office ("USPTO") for a proprietary methodology in the ... the USPTO on August 27th of this year. The ...
... MELBOURNE, Australia, Sept. 3 Cytopia Limited,s (ASX: CYT) ... Food and Drug Administration (FDA) review. CYT387 is a small-molecule ... The company,s IND application is now active and Cytopia is ... United States. , , CYT387 will be ...
Cached Medicine Technology:United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy 2United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy 3Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials 2
... Plate Shaker are designed to give reliable performance ... microplates. The on/off button, power supply socket and ... of the unit. The speed knob is located ... of speed from a minimum 950 rpm to ...
ThermoPrep 3's two systems in "one" approach, its capability to accommodate up to two standard microplates and its user-selectable settings offers the versatility and throughput you need in today's l...
The BD LSR II can be configured with up to four fixed alignment lasers and the ability to detect up to 15 colors, utilizing a revolutionary optical design. The BD LSR II can be configured with a 488 ...
Modular flow cytometer with all options....
Medicine Products: